Merrimack Pharmaceuticals Stock News

Shares of Merrimack Pharmaceuticals Inc. MACK, +224.14% skyrocketed 199.5% toward a 4 1/2-year high in morning trading Wednesday, after the France-based biopharmaceutical company Ipsen IPSEY, +1.39% I

MACK has a $225m milestone if its drug Onivyde works in first-line pancreatic cancer (already approved in second-line). The stock has been badly misvalued because the vast majority of pancreatic cance

Gainers Acorda Therapeutics, Inc. (NASDAQ: ACOR) surged 163.8% to close at $0.8970 on Monday after the company announced a $16.5 million award and royalty/supply relief in the AMPYRA arbitration case

Merrimack Pharmaceuticals press release (MACK): FY GAAP EPS of -$0.18.As of December 31, 2021, Merrimack had cash and cash equivalents and investments of $14.2 million, compared to…

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Mar. 9, 2022-- Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) (“Merrimack” or the “Company”) today announced its full year 2021 financial results for the period ended December 31, 2021 . “During 2021 we have continued to reduce our operating expenses and remain

Renaissance Technologies LLC reduced its holdings in shares of Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) by 45.8% during the second quarter, HoldingsChannel.com reports. The fund owned 101,970 shares of the biopharmaceutical companys stock after selling 86,191 shares during the quarter. Renaissance Technologies LLCs holdings in Merrimack Pharmaceuticals were worth $652,000 as of its most recent filing with []

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) (“Merrimack” or the “Company”) today announced its second quarter 2021 financial results for the period ended J

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Merrimack Reports Full Year 2020 Financial Results

Merrimack Reports Second Quarter 2020 Financial Results

Merrimack Reports Second Quarter 2020 Financial Results

Just because a business does not make any money, does not mean that the stock will go down. For example, although...

Merrimack Pharmaceuticals Inc (NASDAQ:MACK) insider Gary L. Crocker sold 117,963 shares of Merrimack Pharmaceuticals stock in a transaction that occurred on Wednesday, July 22nd. The shares were sold

Merrimack Pharmaceuticals (NASDAQ:MACK) and Ardelyx (NASDAQ:ARDX) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of th